BLTE vs HELP: fair value comparison
Belite Bio, Inc and Cybin D/B/A Helus Pharma · Updated 2026-10-19
BLTE's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. HELP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BLTE currently ranks higher by quality score.
| BLTE | HELP | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $142.78 | $10.55 |
| 12-month range | $92.22–$193.61 | $3.87–$14.02 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #292 of 301 Healthcare | #293 of 301 Healthcare |
| Quality grade | F | F |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BLTE fair value analysis · HELP fair value analysis